Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674654 | 0.88 | PIK3CD (0.45) | PIK3CDPIK3CACYP3A4GBA1PIK3CB | |
| SCHEMBL2673516 | 0.83 | PIK3CD (0.67) | PIK3CDPIK3CACYP3A4PIK3CB | |
| SCHEMBL2673202 | 0.81 | PIK3CD (0.43) | PIK3CDPIK3CACYP3A4GBA1PIK3CB | |
| SCHEMBL4546716 | 0.72 | PIK3CD (0.68) | PIK3CDPIK3CACYP3A4PIK3CBPIK3R1 | |
| SCHEMBL2674658 | 0.71 | PIK3CA (0.50) | PIK3CDPIK3CAPIK3CB | |
| SCHEMBL2674411 | 0.71 | PIK3CD (0.48) | PIK3CDPIK3CACYP3A4PIK3CB | |
| SCHEMBL2673928 | 0.71 | PIK3CD (0.55) | PIK3CDPIK3CACYP3A4PIK3CBPIK3R1 | |
| SCHEMBL2675774 | 0.69 | PIK3CD (0.43) | PIK3CDPIK3CACYP3A4PIK3CB | |
| SCHEMBL10276529 | 0.68 | PIK3CD (0.40) | PIK3CDPIK3CACYP3A4 | |
| SCHEMBL10275774 | 0.68 | PIK3C3 (0.39) | PIK3CACYP3A4GBA1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394796-B2 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use | GENENTECH, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178736-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | PIK3CD 3/4885PIK3CA 1/4885CYP3A4 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.